Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 18, 2013 09:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SAN RAFAEL, Calif., April 18, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that on April 15, 2013, the compensation committee of BioMarin's board of directors...
April 04, 2013 09:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin to Host First Quarter 2013 Financial Results Conference Call and Webcast on Thursday, April 25 at 5:00 p.m. ET

SAN RAFAEL, Calif., April 4, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaimé, Chief Executive Officer of BioMarin, will host a...
April 01, 2013 09:02 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Submits CTA for BMN-190 for Batten Disease

SAN RAFAEL, Calif., April 1, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has submitted a Clinical Trial Application (CTA) with the Medicines and...
April 01, 2013 09:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Submits Vimizim BLA to the U.S. FDA for the Treatment of MPS IVA

SAN RAFAEL, Calif., April 1, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug...
March 25, 2013 09:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Completes Additional Partial Exchange of Convertible Notes Due 2017 for Common Stock

SAN RAFAEL, Calif., March 25, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that an additional six holders of its 1.875% Convertible Senior Subordinated Notes due...
March 19, 2013 16:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin to Advance BMN-701 for Pompe Disease to Next Phase of Development

BMN-701 Meaningfully Improves Respiratory Endpoints Phase 2/3 Switch Study Expected to Begin by December 2013 Conference Call and Webcast to Be Held Today at 5:00 p.m. ET SAN RAFAEL, Calif.,...
March 19, 2013 09:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NOVATO, Calif., March 19, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that on March 15, 2013, the compensation committee of BioMarin's board of directors...
March 18, 2013 09:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Completes Partial Exchange of Convertible Notes Due 2017 for Common Stock

SAN RAFAEL, Calif., March 18, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that seven holders of its 1.875% Convertible Senior Subordinated Notes due 2017 have...
February 28, 2013 09:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin to Attend Upcoming Conferences: Cowen Healthcare Conference, Credit Suisse Global Healthcare Conference and Barclays Global Healthcare Conference

SAN RAFAEL, Calif., Feb. 28, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that BioMarin will attend the Cowen Healthcare Conference in Boston on March 4th, the...
February 21, 2013 16:03 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Announces Fourth Quarter and Full Year 2012 Financial Results

Total Revenue in 2012 Exceeds $500 Million PEG-PAL End of Phase 2 Meeting Completed, Phase 3 to Begin Next Quarter Conference Call and Webcast to Be Held Today at 5:00 p.m. ET Financial...